Erica DiNapoli

Pembrolizumab plus axitinib continued to significantly improve efficacy over sunitinib in patients with previously untreated metastatic renal cell carcinoma, according to updated results from the phase 3 KEYNOTE-426 trial.

Eric Jonasch, MD, on the favorable efficacy and tolerability of MK-6482 in patients with Von Hippel-Lindau disease–associated renal cell carcinoma.

Hatem Soliman, MD, discusses new therapeutic approaches for patients with metastatic triple-negative breast cancer.

Solange Peters, MD, discusses the promising clinical activity observed with trastuzumab deruxtecan in patients with HER2-mutated NSCLC, next steps for research, and other exciting lung cancer data.

Courtney D. DiNardo, MD, MSCE, discusses the results of the study evaluating the combination of azacitidine plus venetoclax in elderly patients with AML.

John P. Leonard, MD, discusses the FDA approval of tazemetostat in patients with follicular lymphoma.

Michael J. Morris, MD, discusses the combination of atezolizumab and radium-223 dichloride, which did not demonstrate a clinical benefit in patients with metastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the implementation of systematic germline genetic testing in veterans with metastatic prostate cancer appeared to be feasible due to high consent rates, especially with direct oncologist involvement.

Pembrolizumab demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer.

The addition of apalutamide to androgen deprivation therapy, significantly improved overall survival and metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer.

Neoadjuvant systemic therapy was found to show a modest benefit in patients with retroperitoneal sarcoma, and the tumor response could be used as an indicator of disease biology to predict survival outcomes after surgery.

Alexander Eggermont, MD, PhD, discusses the impact of the 3-year follow-up data from the phase 3 double-blind EORTC 1325/KEYNOTE-054 trial in high-risk stage III melanoma.